The FDA has released updated draft guidance on population pharmacokinetics (PK). The update follows draft guidance originally put forth by the agency in 1999.
The FDA has released updated draft guidance on population pharmacokinetics (PK). The update follows draft guidance originally put forth by the agency in 1999.
The guidance aims to assist developers submitting New Drug Applications and Biologics License Applications (BLAs) with applying population PK analysis, which quantifies and explains the variability in drug concentrations among individuals and can sometimes reduce the need for postmarketing requirements or commitments.
Because stand-alone studies are usually designed to focus on intrinsic and extrinsic factors that have a high potential to affect drug exposure, they leave other possible interactions unstudied; population PK analysis allows for an assessment of multiple factors that are not otherwise evaluated in healthy volunteers and allows for a large number of patients to be included.
According the updated draft guidance, sponsors are encouraged to use all available data to support their population PK models; data sets should include a sufficient number of subjects with adequate PK samples at informative timepoints, and sponsors should be aware that, as the number of samples per subject decreases, the importance of the timing of PK sampling increases. Sponsors are encouraged to collect PK data from all included patients.
The guidance also provides a description of methodological aspects of population PK analysis, including examination of the observed data, model development, model validation, and simulations based on population PK models. It also outlines the recommended content and format for a drug sponsor to submit its population PK analysis in support of its clinical pharmacology program.
Population PK is becoming an increasingly important way for drug sponsors to provide information about the impact of multiple factors on the PK of their products; one recent study reported that biologics whose data included population PK models most frequently included body size as a covariate in final models, although age, sex, race, and renal function are also included in some models. In 70% to 90% of cases in which these covariates are examined, information from the population PK studies is eventually included in product labels.1
According to another recent paper, population PK modeling and simulation analysis is almost always a component of BLAs for novel drugs, and these analyses can provide a robust knowledge base to support biosimilar development, as they can help with optimizing study design.2
Reference
1. Ogasawara K, Alexander GC. Use of population pharmacokinetic analyses among FDA-approved biologics [published online February 1, 2019]. Clin Pharamcol Drug Dev. doi: 10.1002/cpdd.658.
2. Wang YC, Wang Y, Schrieber SJ, et al. Role of modeling and simulation in the development of novel and biosimilar therapeutic proteins. J Pharm Sci. 2019;108(1):73-77. doi: 10.1016/j.xphs.2018.10.053.
Partnering for Biosimilar Security: India's Role in US Health Care Savings, Supply Chain Stability
May 9th 2024As Indian pharmaceutical companies supplied 4 of every 10 prescriptions in the US in 2022, generating $1.3 trillion in health care savings, a new IQVIA report highlights concerns about supply chain risks and advocates for partnerships to bolster biosimilar security and overall supply chain resilience.
Exploring the Biosimilar Horizon: Julie Reed's Predictions for 2024
February 18th 2024On this episode of Not So Different, Julie Reed, executive director of the Biosimilars Forum, returns to discuss her predictions for the biosimilar industry for 2024 and beyond as well as the impact that the Forum's 4 new members will have on the organization's mission.
A New Chapter: How 2023 Will Shape the US Biosimilar Space for 2024 and Beyond
December 31st 2023On this episode of Not So Different, Cencora's Brian Biehn and Corey Ford take a look back at major policy and regulatory advancements in 2023 and how these changes will alter the space going forward.
Eye on Pharma: EU Ustekinumab Approval; New Golimumab Data; Evernorth Adds Humira Biosimilar
April 29th 2024The European Union gained a new ustekinumab biosimilar; Alvotech released positive results from a clinical trial evaluating a golimumab biosimilar and the reference products (Simponi and Simponi Aria), and Evernorth announced that it is set to cover an adalimumab biosimilar at zero cost to patients.